Copay & Financial Assistance Programs

Analysis

340B Contract Pharmacy Restrictions: What Manufacturers and Vendors Need to Know in 2026

2026 field guide to 340B contract pharmacy restrictions: manufacturer policies, Eighth/Third/D.C. Circuit rulings, state laws, the vacated rebate pilot, and vendor selection impact.

Analysis

Biosimilar Launch Playbook: Hub, Copay & SP Strategy

Analysis of the hub services, copay assistance, and specialty pharmacy strategy specific to biosimilar launches — a structurally different commercial model from innovator biologics that requires recalibrated vendor selection, program design, and economic assumptions.

Analysis

Conflict of Interest in Pharma Commercial Services: A Manufacturer's Framework

Conflict of interest is now a core vendor-selection variable in pharma commercialization, not a legal afterthought. PBM-owned specialty pharmacies, distributor-owned hubs, full-stack commercialization platforms, copay maximizer operators, and data-rich service vendors can all create value through integration, but the same integration can redirect prescriptions, obscure economics, constrain data rights, or weaken manufacturer control over the patient journey.

Comparison

Pharma Copay Program Vendors: ConnectiveRx vs Valeris vs Phil vs Apollo Care

Head-to-head comparison of four copay and financial assistance platforms for pharmaceutical manufacturers. Spans legacy per-redemption processors to digital-first orchestration.

Analysis

Digital Access Operating Models: Affordability, Hub, and Direct-to-Patient

Buyer guide to pharma digital access models across affordability, hub, and DTP programs, comparing TailorMed, RIS Rx, BlinkRx, Phil, Gifthealth, Fuze Health, Atlantis Health, and IntegriChain.

Guide

Field Reimbursement Managers (FRMs): What They Do, Cost, and How to Deploy

Operator guide to FRM programs: functions, loaded-cost modeling, territory sizing, deployment vendors, hub integration, and ROI measurement for specialty launches.

Analysis

GLP-1 Services Crunch: Which Pharma Services Vendors Scale to 10M Patients?

Institutional analysis of which pharma services vendors can scale to GLP-1 volumes. Hubs, AI-PA, retail shift, DTC/telehealth, compounding, and the 2027 IRA reset.

Analysis

Hub Services Pricing Benchmarking: What Should Manufacturers Pay?

Hub pricing is opaque because vendors price capacity, transactions, patients, technology, and outcomes in different combinations, while manufacturers often benchmark proposals too late in the launch process. The practical thesis is that hub cost should be evaluated against workflow complexity and revenue impact, not against a generic rate card.

Analysis

IRA Maximum Fair Price: What Rounds 2-3 Mean for Hub, Copay, and Specialty Pharmacy Vendors

How IRA Medicare negotiation Rounds 2-3 (2027-2028 MFPs) restructure vendor economics across hubs, copay, specialty pharmacy, 340B, and market access consulting.

Analysis

Part D Redesign 2025-2026: The End of Copay Accumulators and the New Patient Economics

How the 2025 Part D redesign, $2,000 OOP cap, Manufacturer Discount Program, and smoothing rewrite manufacturer economics and neutralize accumulator value.

Analysis

Payer Landscape Overview: Plan Design, Self-Insured Dynamics & Formulary Strategies

Analysis of the U.S. commercial and government payer landscape as it relates to pharmaceutical services vendor selection. This page provides the demand-side context that shapes hub services, copay assistance, specialty pharmacy, and prior authorization vendor requirements.

Analysis

PBM Reform 2026: What CAA, FTC, State Divestitures, and Transparency Rules Mean for Pharma Vendor Strategy

How the FTC Express Scripts settlement, CAA 2026, Arkansas Act 624, and federal delinking proposals are reshaping specialty pharmacy, hub services, and manufacturer GTN strategy.

Analysis

PBM Reform Implications for Pharma Services Vendors

PBM reform is accelerating across federal, state, and regulatory levels. The convergence of the FTC investigation, Consolidated Appropriations Act of 2026 (CAA), state PBM divestiture legislation, and copay accumulator/maximizer restrictions is reshaping the competitive landscape for every pharma services vendor category. This analysis maps the specific implications for hub services, specialty pharmacies, copay assistance vendors, and market access consultants.

Analysis

PBM Transparency & Pass-Through Economics

Big 3 PBM opacity economics — spread pricing, rebate retention, self-preferencing to affiliated specialty pharmacies — face the most serious structural threat since the modern PBM model emerged in the early 2000s.

Guide

Pharma Services Explained: Hub, Specialty Pharmacy, FRM, and How They Fit Together

Lexicon guide to the pharma commercial services stack. Hub vs specialty pharmacy vs field reimbursement vs copay processor vs market access, with pricing models and named vendors.

Analysis

US Pharma Services Market Sizing and 2025 Update

Directional U.S. pharma services market sizing across specialty pharmacy, prior authorization and reimbursement support, copay programs, market access consulting, data/RWE, and commercial technology, with the 2025 banking-report update folded into one public market map.

Guide

Rare Disease Launch: Vendor Stack Playbook

A prescriptive vendor-stack playbook for rare disease launch teams — sequenced T-18 to T+6 with named vendors, pricing benchmarks, and decision trade-offs for orphan drug commercialization.

Analysis

Specialty Pharmacy Competitive Landscape

U.S. specialty pharmacy landscape analysis covering PBM-owned scale platforms, independent clinical specialists, and health-system specialty pharmacy growth.

Listicle

Top 10 Specialty Pharmacies for Pharma Manufacturers (2026)

Ranking and analysis of the top 10 specialty pharmacies serving pharma manufacturers, covering PBM-owned, independent, payer-owned, retail-adjacent, and health-system accelerator models.